PMID: 6538740May 1, 1984Paper

Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease

The American Journal of Cardiology
E ThaulowE Myhre

Abstract

Thromboxane A2 (TxA2) may aggravate myocardial ischemia by inducing vasoconstriction and platelet aggregation in small coronary vessels, whereas prostacyclin (PGI2) counteracts these effects. Acetylsalicylic acid (ASA) inhibits the formation of TxA2 as well as PGI2, whereas dazoxiben, a thromboxane synthetase inhibitor, reduces TxA2 formation selectively. In 25 patients with coronary artery disease, 2 identical atrial pacing stress tests were performed: before and after the administration of dazoxiben (200 mg) in 15 patients and before and after ASA (250 mg) in 10. The ischemic response, quantified by coronary sinus and aortic lactate levels and by ST depression, was significantly reduced after administration of dazoxiben (p less than 0.02) but not after ASA. Heart rate at rest, myocardial extraction of free fatty acids and the arteriovenous oxygen difference was unaffected by medication. Both drugs reduced TxB2 levels to the same extent, whereas collagen-induced aggregation was more reduced after ASA than after dazoxiben. The effect of dazoxiben on ischemia was probably a result of inhibited TxA2 and preserved PGI2 production, which increased blood flow to ischemic regions.

References

Dec 1, 1976·Scandinavian Journal of Clinical and Laboratory Investigation·H Vik-Mo, O D Mjös
Jul 1, 1971·The Journal of Clinical Investigation·O D Mjos
Jul 1, 1970·Analytical Biochemistry·R J Ho
Sep 1, 1983·The American Journal of Cardiology·E Thaulow
Feb 1, 1983·Scandinavian Journal of Clinical and Laboratory Investigation·H IhlenE Thaulow
Jan 1, 1983·British Journal of Clinical Pharmacology·P S KiffV V Kakkar
Jan 1, 1983·British Journal of Clinical Pharmacology·I HuttonJ F Davidson

❮ Previous
Next ❯

Citations

Dec 1, 1989·Cardiovascular Drugs and Therapy·B Stein, V Fuster
Jan 20, 1987·European Journal of Pharmacology·C L Wainwright, J R Parratt
Oct 1, 1989·Journal of the American College of Cardiology·B SteinJ H Chesebro
Jul 1, 1988·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G M PieperG J Gross
Mar 3, 1998·Blood Reviews·J E Joseph, S J Machin
Dec 1, 1986·Journal of Cardiac Surgery·W J GreeleyW D Watkins
Jan 15, 1986·Thrombosis Research·Z TerashitaS Terao
Oct 1, 1985·Circulation·P M Vanhoutte, D S Houston
Dec 1, 1985·Circulation·G A FitzGeraldA K Pedersen
Oct 16, 1986·The New England Journal of Medicine·D J FitzgeraldG A FitzGerald
Jan 1, 1987·Pharmacotherapy·R E Nitz, V B Fiedler
Aug 1, 1987·Journal of Cardiothoracic Anesthesia·W J GreeleyJ G Reves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.